• SAG: Smoothened Receptor Agonist Workflows in Hedgehog Assay

  2026-05-15

  Harness the precision of Smoothened Agonist (SAG) for robust Hedgehog pathway activation in developmental, neuroregenerative, and disease modeling research. This guide details experimental workflows, troubleshooting, and the latest insights from functional assays, enabling reproducible results in stem cell, tumorigenesis, and cerebellar abnormality studies.

• Optimizing Hedgehog Pathway Activation with SAG: Protocols &

  2026-05-15

  Smoothened Agonist (SAG) is a gold-standard tool for robust Hedgehog pathway activation, enabling precise experimental control in developmental biology, disease modeling, and neuroprotection research. This guide delivers evidence-backed workflows, protocol parameters, and troubleshooting strategies—empowering researchers to maximize reproducibility and interpretability when employing SAG in complex assays.

• 4-Hydroxytamoxifen: Technical Guidance for Research Protocol

  2026-05-14

  4-Hydroxytamoxifen is a high-purity estrogen receptor modulator designed for in vitro and in vivo research applications, including breast cancer, prostate cancer, and cardiac myocyte studies. It should be used only in protocols requiring DMSO solubility and is unsuitable for workflows needing aqueous or ethanol solvents. Strict storage and handling practices are required to preserve reagent integrity and ensure reproducibility.

• Small Molecule Inhibitors of Shh/Heparin Binding: Pathway In

  2026-05-14

  Lamson et al. conducted a high-throughput screen to identify small molecules that antagonize Sonic hedgehog (Shh) binding to heparin, an interaction critical for Hedgehog pathway activity in development and cancer. Their discovery of pathway-selective inhibitors reveals a new targetable interface in Shh signaling and provides tool compounds for dissecting ligand-specific mechanisms.

• SGC-CBP30: Precision CREBBP/EP300 Bromodomain Inhibitor for

  2026-05-13

  SGC-CBP30 empowers researchers to dissect transcriptional coactivator inhibition in complex cancer and epigenetics research models. This guide translates high-impact findings from early-stage lung adenocarcinoma studies into actionable workflows, troubleshooting, and optimization strategies.

• Acetylcholine Chloride: Optimizing Cholinergic Signaling Ass

  2026-05-13

  Acetylcholine Chloride empowers researchers to dissect gut-brain cholinergic pathways, unlocking translational insights for epilepsy and neural circuit modulation. This article details best practices, troubleshooting, and protocol precision for leveraging APExBIO’s high-purity reagent in advanced neurobiology and microbiome research.

• Induction of Right Ventricular Cardiomyocytes from hPSCs

  2026-05-12

  Saito et al. present a refined differentiation protocol that enables the specific generation of right ventricular-like cardiomyocytes from human pluripotent stem cells. This innovation provides a platform for chamber-specific heart disease modeling and enhances understanding of right ventricular pathology.

• Alternariol Induces Liver Fibrosis via Stellate Cell Activat

  2026-05-12

  This study uncovers how Alternariol (AOH) and related Alternaria toxins drive the transdifferentiation of hepatic stellate cells into myofibroblasts, a key event in liver fibrosis. Through omics-guided analysis, it reveals activation of NF-κB, ferroptosis, and autophagy pathways, and introduces CotA laccase as a candidate for mycotoxin detoxification.

• Quizartinib (AC220): Optimizing Selective FLT3 Inhibition in

  2026-05-11

  Quizartinib (AC220) empowers acute myeloid leukemia research with nanomolar FLT3 inhibition and robust selectivity, offering unmatched utility in both in vitro and in vivo models. This guide translates recent advances—such as targeting FLT3-driven resistance—into practical protocols, troubleshooting strategies, and comparative insights for highly reproducible results.

• Rottlerin: Precision PKCδ Inhibition for Translational Impac

  2026-05-11

  Explore how Rottlerin, a selective PKCδ inhibitor, transforms translational research by bridging mechanistic insight with evidence-based guidance. This article dissects its role in modulating cell proliferation, apoptosis, and viral entry, connecting peer-reviewed findings with workflow optimization and competitive positioning for advanced applications.

• Dehydroepiandrosterone (DHEA): Optimizing Neuroprotection an

  2026-05-10

  Leverage Dehydroepiandrosterone (DHEA) for robust models in neuroprotection and ovarian biology, with protocol-ready parameters and troubleshooting tips informed by the latest research. Discover how APExBIO’s DHEA streamlines experimental success, from apoptosis inhibition to granulosa cell proliferation.

• MAPK10 Phosphorylation of KRT16 Suppresses NSCLC Metastasis

  2026-05-09

  This study reveals that mitogen-activated protein kinase 10 (MAPK10) inhibits non-small cell lung cancer (NSCLC) metastasis by promoting phosphorylation-dependent ubiquitination and degradation of keratin 16 (KRT16). The findings identify the MAPK10/KRT16/RNF213 axis as a potential prognostic biomarker and therapeutic target in NSCLC, opening new avenues for molecular pathway research and intervention.

• EphA2 as a Synthetic Lethal Target in MYC-Driven TNBC: Chemo

  2026-05-08

  This study pioneers a chemogenetic screening strategy to identify synthetic lethal targets in MYC-driven triple-negative breast cancer (TNBC), pinpointing EphA2 inhibition as a promising vulnerability. The findings highlight the therapeutic potential of targeting EphA2 in aggressive, MYC-activated TNBC, with robust experimental validation and translational implications.

• CHI3L1-IN-5 (Compound Z17): Optimizing Neuroinflammation Ass

  2026-05-08

  CHI3L1-IN-5 (Compound Z17) empowers translational research by uniquely enabling both suppression of CHI3L1-mediated NF-κB signaling and restoration of amyloid-beta clearance in astrocytes. This protocol-centric guide translates recent mechanistic advances into robust workflows for modeling and modulating neuroinflammatory cascades in Alzheimer's disease.

• Latrunculin A: Reversible Inhibitor of Actin Assembly in Res

  2026-05-07

  Latrunculin A empowers high-precision, reversible actin cytoskeleton disruption for advanced cell morphology and virology studies. Learn how recent proteomic insights and optimized protocols elevate reproducibility and mechanistic clarity in cytoskeletal and host-pathogen research.

764 records 18/51 page Previous Next First page 上5页 1617181920 下5页 Last page